Drug class
Porphyrin-based photosensitiser; photodynamic therapy antineoplastic agent
Mechanism of action
After intravenous administration, porfimer accumulates in selected tissues. Exposure to appropriate wavelength light generates reactive oxygen species, causing local cellular injury, vascular damage and tumour necrosis.
General use cases
- Photodynamic therapy for microinvasive endobronchial non-small-cell lung cancer (NSCLC) in patients for whom surgery and radiotherapy are not indicated
- Palliation of symptoms and obstruction in patients with completely or partially obstructing endobronchial NSCLC; treatment requires light activation and careful protection from photosensitivity
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
